Beam Therapeutics Inc. ( BEAM ) shares are up during Wednesday’s premarket session following the release of promising clinical data regarding its treatment BEAM-302.

BEAM-302 is Beam’s lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.

AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease.

Data Show AAT Levels Above Protective Threshold

The company announced updated safety and efficacy data from its ongoing Phase 1/2 trial of BEAM-302, highlighting that treatment with 60 mg of the drug led to a mean steady-state total alpha-1 antitrypsin (AAT) level of 16.1 µM.

Notably, all patients remained consistently and durably above the 11 µM protective AAT threshold, with a significant reduction in mutant Z-AAT levels.

Additionally, the trial demonstrated a well-tolerated safety profile, with no serious adverse events reported.

The company plans to initiate a global pivotal cohort in the second half of 2026, further advancing its efforts in treating alpha-1 antitrypsin deficiency (AATD).

BEAM-302 Pivotal Development

Based on feedback from the U.S. Food and Drug Administration (FDA), Beam intends to pursue an accelerated approval pathway for BEAM-302 based on a primary endpoint of AAT biomarkers evaluated over 12 months, with 60 mg as the selected dose.

To support a future biologics licensing application (BLA) submission, the company anticipates enrolling approximately 50 additional patients with AATD-associated lung disease, with or without liver disease, in an expansion of the ongoing open-label Phase 1/2 trial.

Beam expects to initiate the pivotal cohort in the second half of 2026.

Technical Indicators Reflect Mixed Momentum

Currently, Beam Therapeutics ( BEAM ) is trading 7.5% below its 20-day simple moving average (SMA) and 8.7% below its 100-day SMA, indicating some short-term weakness.

Over the past 12 months, shares have increased by 3.14% and are currently positioned closer to their 52-week highs than lows.

The RSI is at 38.84, which is considered neutral territory, while the MACD is at -0.9269, below its signal line at -0.7546, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

Key Resistance: $29.00

Key Support: $23.50

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $47.57. Recent analyst moves include:

RBC Capital: Sector Perform (Raises Target to $26.00) (Feb. 25)

Wedbush: Outperform (Raises Target to $65.00) (Feb. 25)

Canaccord Genuity: Initiated with Buy (Target $74.00) (Feb. 20)

Top ETF Exposure

ARK Innovation ETF ( ARKK ) : 3.60% Weight

ARK Genomic Revolution ETF ( ARKG ) : 4.96% Weight

BEAM Stock Price Activity: Beam Therapeutics ( BEAM ) shares were up 2.71% at $24.60 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock